Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy

Conditions

• Severe Sepsis
• Coagulopathy

Interventions

• DRUG: ART-123
• DRUG: Placebo

Sponsor

Asahi Kasei Pharma America Corporation